CRS1 Stock Chart & Stats
€3.40
-€0.05(-1.27%)
At close: 4:00 PM EST
€3.40
-€0.05(-1.27%)
Day’s Range― - ―
52-Week Range€2.21 - €3.56
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€318.20M
Enterprise Value€473.37
Total Cash (Recent Filing)€70.55M
Total Debt (Recent Filing)€226.18M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding91,436,195
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€662.80M
Bulls Say, Bears Say
Bulls Say
Cash GenerationErcros has shown the ability to convert operations into cash with positive operating and free cash flow in 2025. Durable cash generation supports working-capital needs, funds maintenance capex and operations through cycles, and provides liquidity even if earnings remain volatile.
Industrial Customer Base & Contract SalesThe business model centers on selling basic chemicals to industrial customers under supply contracts and spot orders. This mix and exposure to industrial demand create recurring revenue potential, steady tonnage-based sales, and pass-through pricing ability for some cost items, helping long-term revenue resilience.
Moderate Absolute LeverageAlthough leverage has risen, total debt remained below equity in 2025. That moderates insolvency risk, provides a buffer for cyclical downturns, and preserves some capacity to access financing for capex or restructuring versus peers that are heavily overlevered.
Bears Say
Profitability DeteriorationErcros's shift from solid profits into successive losses through 2024–2025 signals structural margin pressure. Persistent losses erode retained earnings, limit reinvestment ability, and indicate difficulty in restoring prior margin levels without sustained demand or cost improvements.
Declining Revenue TrendA multi-year top-line decline reduces operating leverage at production sites and increases per-unit fixed costs. Lower utilization undermines margin recovery potential, makes cost absorption harder, and increases sensitivity of earnings to further demand softness.
Rising Leverage And Falling EquityThe meaningful increase in debt-to-equity and declining shareholder equity reduce the company’s financial flexibility. This trend raises refinancing and covenant risks, increases interest burdens if rates rise, and limits capacity to fund growth or absorb extended downturns.
Ercros SA News
CRS1 FAQ
What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest stock price was €2.21 and its highest was €3.56 in the past 12 months.
What is Ercros SA’s market cap?
Ercros SA’s market cap is €318.20M.
When is Ercros SA’s upcoming earnings report date?
Ercros SA’s upcoming earnings report date is Nov 11, 2026 which is in 98 days.
How were Ercros SA’s earnings last quarter?
Ercros SA released its earnings results on Jul 28, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ercros SA overvalued?
According to Wall Street analysts Ercros SA’s price is currently Overvalued.
Does Ercros SA pay dividends?
Ercros SA does not currently pay dividends.
What is Ercros SA’s EPS estimate?
Ercros SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ercros SA have?
Ercros SA has 91,436,195 shares outstanding.
What happened to Ercros SA’s price movement after its last earnings report?
Ercros SA reported an EPS of -€0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.86%.
Which hedge fund is a major shareholder of Ercros SA?
Currently, no hedge funds are holding shares in DE:CRS1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ercros SA
Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Repsol
―





